Best Floyd County Grants for Nonprofits in Virginia

Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding Disorders 

There remains a scientific gap in understanding of the role of anti-TFP Imediated hemostatic rebalancing in the context of inherited or non-hemophilic bleeding disorders. This competitive grant program encourages competitive submissions focsed on generating preclinical/foundational data exploring the therapeutic potential and mechanisms of TFPI modulation in bleeding disorders other than hemophilia.

Geographic Scope

Brazil, China, Europe, Israel, Japan, Saudi Arabia, South Korea, Turkey, USA

Funding Range and Project Length

Individual projects requesting up to $50,000 USD will be considered.

Request for study drug or compound is allowed (max $50,000 USD), additionally to the study project costs.

Maximum project length is 1 year.

Pediatric Hidradenitis Suppurativa Challenge Grant

Hidradenitis suppurativa (HS) is a devastating chronic inflammatory disease that manifests as recurrent painful nodules under the skin in the intertriginous areas of the body. It is associated with significant impacts on quality of life, psychosocial well-being, and long-term health outcomes of patients as well as consequences for families and caregivers. HS is prevalent, affecting between 1 and 4% of the population beginning in adolescence and persisting into adulthood. Despite the impact of HS, it remains underdiagnosed, undertreated, and understudied particularly in the pediatric and adolescent populations. Contributing to this dynamic are unknowns related to a complex disease etiology, stigma associated with HS symptoms (e.g., sweating, itching, and scarring commonly in the genital region), and limited treatment options to date with even fewer available for children under the age of 12.

To address the needs of children and adolescents living with HS, the Pediatric Dermatology Research Alliance (PeDRA), HS Connect, and the HS Foundation are offering the 2026 Pediatric HS Challenge Grant to support an early-to-mid career investigator for a one-year project focused on a high-priority, patient-centric research topic.

Focus

Proposals should address one or more of the following high-priority research topics:

• Predicting treatment effectiveness and risk utilizing real world evidence and/or experience
• Early disease and factors involved in severe disease development
• Optimizing surgical and procedural approaches to minimize pain, shorten healing time, and reduce recurrence
• Improving recruitment of diverse and representative populations for clinical studies, trials and advanced therapeutics

Funding:

• Up to $50,000 to support one year of research
• One award anticipated for this funding cycle

The Alpha Omega Alpha/Pharos Poetry Award

To encourage students to write effective poetry. Winning poems are published in The Pharos.

The Award

Up to 5 poems will receive a $1,500 award. The winning entries will be published in The Pharos.

Summer Medical Internship Program (SMIP)

Fosters an interest in research by funding a summer research project conducted by a medical student.

The SIR Foundation Summer Medical Internship Program introduces medical students to interventional radiology research and medical device development. The goal of this program is to foster an interest in research by funding a summer research project conducted by a medical student.

Students applying for the program must show strong potential for a career in IR with proven academic success. Selected students will have an opportunity to intern with an interventional radiologist research mentor or corporate research and development mentor for 8 weeks during the summer.

SIR Foundation will provide a $6,000 stipend to help ease the financial burdens throughout their internship experience.

• Budget: Up to $6,000
• Grant Length: Eight weeks

Hilcorp Future Leaders of America Scholarship

Benefiting select communities across the United States where Hilcorp operates.

The Hilcorp Future Leaders of America Scholarship Program was developed to give back to the communities in which Hilcorp Energy Company operates to develop future leadership talent as the next innovators, educators, and business leaders.

Award Amount

Multiple scholarships awarded annually. The scholarship is comprised of up to four (4) annual awards of $2,500, for a total award of up to $10,000.

The four annual (4) awards may be received over a period of up to 6 years, allowing for deferment if needed.

GBA1 Parkinson's Disease Research Catalyst Program

The GBA1-PD Research Catalyst Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis- driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the research community.

Funding

Duration: 12 to 24 months

Award Amount: Up to $300,000. Requested support should be commensurate with work proposed.

These budgets include direct and indirect costs. For academic and for-profit institutions, no more than 15% or 10%, respectively, may go to indirect costs. 

Patrick J. Kiley / Houston AGC Scholarship

Benefiting employees, dependents of employees, and/or interns of AGC Houston member firms OR students involved in AGC Student Chapters.

Award Amounts

Multiple awards are given each year. Scholarship award amounts will vary for each selected scholarship recipient.

Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata: A Real-World Evidence Approach

Alopecia Areata (AA) is a chronic, immune-mediated condition causing nonscarring hair loss that affects about 2% of the global population and can lead to substantial psychosocial burden if disease is severe and untreated. The treatment landscape has recently evolved with the approval of ritlecitinib, a systemic therapy for severe AA in adults and adolescents aged 12 years and older, based on efficacy demonstrated in the ALLEGRO phase 2b/3 program.

Despite this advance, important questions remain regarding the optimal timing of therapy initiation. Emerging post-hoc analyses from the ALLEGRO program indicate that patients with shorter disease duration and lower baseline severity achieve higher response rates, suggesting that earlier intervention with ritlecitinib may lead to improved outcomes.

Geographic Scope

United States 

Funding Range and Project Length

Individual projects requesting up to $100,000 USD will be considered.

Maximum project length is 24 months.

Hemophilia Fellowship

This competitive grant program seeks to support an institution-based fellowship that emphasizes shared decision making (SDM), patient education, and multidisciplinary team-based care. The intent is to strengthen the hemophilia care through equitable education, and patient-centered shared decision making in a rapidly evolving treatment landscape.

Geographic Scope

• United States 

Funding Range and Project Length

• Grant funding is available to support a one year fellowship up to $100.000 USD. 

Accelerating the Development of Combined CGM–Pump Devices

A combined continuous glucose monitor (CGM) and insulin pump device represents an innovative approach to simplifying diabetes management by integrating two essential technologies into a single device. This approach has the potential to improve quality of life for people with type 1 diabetes (T1D) by reducing the burden associated with wearing and managing multiple devices.

Despite this promise, the development of combined CGM–pump devices presents technical and commercialization challenges. These include the need for further advances in device compatibility and lifespan, system reliability, and scalable manufacturing, while maintaining affordability and broadaccessibility. In addition, a potential insulin dilution effect may require adjustment of the CGM algorithm.

Breakthrough T1D invites applications for research and development projects that address key technical, clinical, and translational challenges related to combined CGM–pump devices, with the goal of accelerating their development and improving outcomes for people living with T1D.

In response to this announcement, applications may request up to a total of $900,000 USD for up to three years.